Insights - Menlo (MNLO), a company developing serlopitant for chronic cough candidate, reported disappointing Phase 2 data. In 185 patients, serlopitant group had 31% less reduction than the placebo group. In … Continue Reading
Read NowInsights - Selecta will present their “5+0” co-administered Phase 2 data at the American College Rheumatology (ACR) conference held October 19-24 in Chicago. What to expect 1. … Continue Reading
Read NowInsights - For the first time since PropThink launched in late 2012, we travelled to a Patient Advocacy Meeting in Maryland – to see and hear from … Continue Reading
Premium: Read NowInsights - In December, Bellus Health (BLUSF:OTC) (BLU:TSX) will report Phase 1 data for their chronic cough candidate BLU-5937. Bellus’ candidate is a P2X3 inhibitor, a class … Continue Reading
Read NowInsights - Selecta released Q2 2018 results and announced updates regarding their Phase 2 SEL-212 5+0 dosing and Phase 3 plans. Here are main takeaways: 5+0 dosing to be … Continue Reading
Read NowInsights - The pediatric committee at the European Medicines Agency (EMA) held discussions last week on Fennec’s STS, which is nearing a MAA submission sometime in Q4. The title … Continue Reading
Premium: Read NowInsights - Our original thesis was that GBT would show a clear improvement in at least 1 of 2 secondary events (in addition to the primary Hb … Continue Reading
Premium: Read Now
